Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 31, 2012, Pages

  Ohashi, Kadoaki ^a   Sequist, Lecia V ^b,c   Arcila, Maria E ^d   Moran, Teresa ^g   Chmielecki, Juliann ^h   Lin, Ya Lun ^a   Pan, Yumei ^a   Wang, Lu ^d   De Stanchina, Elisa ^e   Shien, Kazuhiko ⁱ   Aoe, Keisuke ^j   Toyooka, Shinichi ⁱ   Kiura, Katsuyuki ^k   Fernandez Cuesta, Lynnette ^l   Fidias, Panos ^b,c   Yang, James Chih Hsin ^m,n   Miller, Vincent A ^f   Riely, Gregory J ^f   Kris, Mark G ^f   Engelman, Jeffrey A ^b,c   Vnencak Jones, Cindy L ^o   Dias Santagata, Dora ^c,p   Ladanyi, Marc ^d   Pao, William ^a   more..

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Department of Pathology ^*  (United States)

^e Anti Tumor Assessment Core Facility   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h Weill Cornell Graduate School of Biomedical Sciences   (United States)

ⁱ OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^j NATIONAL SANYO HOSPITAL   (Japan)

^k OKAYAMA UNIVERSITY   (Japan)

^l MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^m Graduate Institute of Oncology   (Taiwan)

ⁿ NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^o VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

Erlotinib; Gefitinib; Nras mutation

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GUANOSINE TRIPHOSPHATASE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; SELUMETINIB;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; COLON CANCER; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG CANCER; MELANOMA; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAP KINASE KINASE 1; MUTATION, MISSENSE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84864524696     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1203530109     Document Type: Article

References (42)

1. Lynch TJ, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139. (Pubitemid 38637993)
2. Paez JG, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500. (Pubitemid 38720929)
3. Pao W, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311. (Pubitemid 39209661)
4. Shigematsu H, et al. (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346. (Pubitemid 40425952)
5. Maemondo M, et al.; North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388.
6. Kobayashi S, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792. (Pubitemid 40271173)
7. Pao W, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73.
8. Balak MN, et al. (2006) Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12:6494-6501. (Pubitemid 44799723)
9. Arcila ME, et al. (2011) Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17:1169-1180.
10. Engelman JA, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043. (Pubitemid 46799492)
11. Bean J, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104:20932-20937.
12. Sequist LV, et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3:75ra26.
13. Zakowski MF, Ladanyi M, Kris MG; Memorial Sloan-Kettering Cancer Center Lung Cancer OncoGenome Group (2006) EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med 355:213-215. (Pubitemid 44050422)
14. Sequist LV, et al. (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 22:2616-2624.
15. Ding L, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075.
16. Paik PK, et al. (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29:2046-2051.
17. Marchetti A, et al. (2011) Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29:3574-3579.
18. Marks JL, et al. (2008) Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 68:5524-5528.
19. Yamamoto H, et al. (2008) PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68:6913-6921.
20. Chaft JE, et al. (2012) Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 11:485-491.
21. Marks JL, et al. (2007) Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. PLoS ONE 2:e426.
22. Kris MG, et al. The NCI's Lung Cancer Mutation Consortium (LCMC) Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma (abstract CRA7506). J Clin Oncol 2011; 29(Suppl). Available at http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=102&abstractID=81670.
23. Pao W, et al. (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17.
24. De Rocck W, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy- refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 11:753-756.
25. Misale S, et al. (2012) Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer. Nature, 10.1038/nature11156.
26. Nazarian R, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977.
27. Wagle N, et al. (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-3096.
28. Agaram NP, et al. (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47:853-859.
29. Kosaka T, et al. (2006) Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 12:5764-5769. (Pubitemid 44629607)
30. Politi K, Fan PD, Shen R, Zakowski M, Varmus H (2010) Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech 3:111-119.
31. Chmielecki J, et al. (2011) Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 3:90ra59.
32. Su Z, et al. (2011) A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 13:74-84.
33. Ogino A, et al. (2007) Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res 67:7807-7814. (Pubitemid 47281375)
34. Ichihara E, et al. (2009) Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res 69:5091-5098.
35. Suda K, et al. (2010) Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 16:5489-5498.
36. Suda K, et al. (2011) Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6:1152-1161.
37. Li D, et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702-4711.
38. Dias-Santagata D, et al. (2010) Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Mol Med 2:146-158.
39. Thomas RK, et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347-351. (Pubitemid 46328493)
40. Regales L, et al. (2009) Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 119:3000-3010.
41. Janjigian YY, et al. (2011) Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib (abstract 7525∧), J Clin Oncol 29 (Suppl). Available at http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail- view&confID=102&abstractID=78057.
42. Ercan D, et al. (2011) Amplification of ERK2 mediates resistance to the novel irreversible EGFR inhibitor WZ4002 (abstr 4736∧). American Association for Cancer Research annual meeting. Available at http://www.abstractsonline. com/Plan/ViewAbstract.aspx?sKey=5dc0a975-14e5-47f5-80d3-4dbd39f02a11&cKey= ffa124f6-5a91-4a2a-9b2f-97f0f288b5d2&mKey=%7b507D311A-B6EC-436A-BD67- 6D14ED39622C%7d.